Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCSL Behring
About this trial
The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).
Eligibility criteria
Qualifiers
Adult patient (aged ≥18 years)
Patients suffering from CIDP according to EAN/PNS 2021 criteria
Planned switch from IVIg to Hizentra®
Patient treated with at least 3 courses of IV immunoglobulin and deemed by the investigator to be dependent on immunoglobulins
Disqualifiers
Concomitant participation in an interventional clinical study
Trial design
Treatments tested in this trial
- Hizentra
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov